These PD-1/PD-L1 monotherapy protocols could be effective in those HCC case with an IFN-γ dominant CD8 T cell infiltrate but those cases without an immune-class phenotype could also benefit from ICI after additional synergic therapies. This evidence concerns the gene CD8A and hepatocellular carcinoma.